Sugi Predict

Sugi Predict / Compounds / SCHEMBL3363261

SCHEMBL3363261

SCHEMBL3363261

N#Cc1ccc2c(c1)CCCC2

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 6/20 0.60
▸ DRD2 P14416 4/20 0.60
▸ DRD3 P35462 4/20 0.60
▸ KDM1A O60341 2/20 0.51
▸ CYP11B2 P19099 2/20 0.42
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ CXCR5 P32302 1/20 0.41
▸ CYP19A1 P11511 3/20 0.40
▸ CYP11B1 P15538 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741121 1.00 PNMT (0.60) PNMTDRD2DRD3KDM1ACYP11B2
SCHEMBL17350029 0.98 PNMT (0.58) PNMTDRD2DRD3KDM1ACYP11B2
Hydrochloric Acid SCHEMBL15205820 0.98 PNMT (0.58) PNMTDRD2DRD3KDM1ACYP11B2
SCHEMBL8222195 0.95 PNMT (0.60) PNMTDRD2DRD3KDM1ACYP11B2
SCHEMBL29618357 0.95 PNMT (0.60) PNMTDRD2DRD3KDM1ACYP11B2
Hydrochloric Acid SCHEMBL30894888 0.93 PNMT (0.58) PNMTDRD2DRD3KDM1ACYP11B2
SCHEMBL22872285 0.86 DRD2 (0.51) PNMTDRD2DRD3KDM1ACYP11B2
SCHEMBL4033305 0.83 PNMT (0.79) PNMTDRD2DRD3
Hydrochloric Acid SCHEMBL21753256 0.81 PNMT (0.76) PNMTDRD2DRD3
SCHEMBL24265308 0.81 DRD2 (0.80) PNMTDRD2DRD3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022155419-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2022-07-21 — — WO claimed
US-10043978-B2 Organic semiconductor formulations FLEXTERRA, INC. (US) 2018-08-07 — — US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 — — US claimed
US-20050182269-A1 Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof ASTRAZENECA AB (SE) 2005-08-18 — — US claimed
EP-1517884-A1 A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF AstraZeneca AB (SE) 2005-03-30 — — EP claimed
WO-2004000792-A1 A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF ASTRAZENECA AB (SE) 2003-12-31 — — WO claimed
EP-4722206-A1 BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES Haihe Biopharma Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-02-26 — — US disclosed
EP-4678634-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF Haihe Biopharma Co., Ltd. (CN) 2026-01-14 — — EP disclosed
WO-2024245408-A1 BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES 上海海和药物研究开发股份有限公司 2024-12-05 — — WO disclosed
WO-2024183793-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF 上海海和药物研究开发股份有限公司 2024-09-12 — — WO disclosed
EP-3394068-B1 TDO2 INHIBITORS GENENTECH INC (US) 2024-09-11 — — EP disclosed
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
US-9293711-B2 Organic semiconductor formulations POLYERA CORPORATION (US) 2016-03-22 — — US disclosed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 — — US disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 — — US disclosed
US-20050222154-A1 Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-10-06 — — US disclosed
US-20050182269-A1 Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof ASTRAZENECA AB (SE) 2005-08-18 — — US disclosed
EP-1517884-A1 A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF AstraZeneca AB (SE) 2005-03-30 — — EP disclosed
WO-2004000792-A1 A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF ASTRAZENECA AB (SE) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182269-A1 Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof CYP8B1, CYP51A1, NISCH PNMT 2138/4885DRD2 4401/4885DRD3 3672/4885
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A PNMT 31/4885DRD2 59/4885DRD3 80/4885
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR PNMT 3066/4885DRD2 3536/4885DRD3 3012/4885
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, LDLR, APOB PNMT 4822/4885DRD2 4337/4885DRD3 3210/4885
US-20050222154-A1 Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents DHPS, TNF, IL1B PNMT 1166/4885DRD2 1433/4885DRD3 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.